Scholarlink

<p>This study introduces a novel approach for non-small cell lung cancer (NSCLC) treatment by developing Bi<sub>2</sub>Se<sub>3</sub>-Polysorbate nanoparticles as a multifunctional platform for photothermal therapy and targeted drug delivery. The Bi<sub>2</sub>Se<sub>3</sub>-Polysorbates nanoparticles are engineered as innovative photosensitive drug carriers, enhancing biocompatibility through the combination of Bi<sub>2</sub>Se<sub>3</sub> and Polysorbates. Characterization techniques such as Fourier-transform infrared spectroscopy (FT-IR), scanning electron microscopy (SEM), transmission electron microscopy (TEM), and ultraviolet-visible (UV-Vis) spectroscopy confirm the successful synthesis of the nanoparticles. In a breakthrough step, these nanoparticles are combined with a novel heterocyclic drug (drug-1), verified by single-crystal analysis, to create the Bi<sub>2</sub>Se<sub>3</sub>-Polysorbates@drug-1 composite. Biological evaluations show that the system significantly inhibits cell proliferation in NSCLC cells, and molecular docking studies reveal that drug-1 interacts with the target protein through hydrogen bonds, halogen bonds, and hydrophobic interactions, suggesting promising anti-cancer activity. This research presents a novel multifunctional nanoplatform for effective drug delivery and offers a new strategy for the treatment of NSCLC, demonstrating significant advancements in cancer therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Fluorescent Heterocyclic Compound-Loaded Bi2Se3-Polysorbate Nanoparticles for Targeted Therapy in Non-Small Cell Lung Cancer

  • 期刊论文

  • 发表日期：

    2025年1月8日

查看全文
  • Binhua Jiang,
  • Gaopeng Zhang,
  • Denghai Wu

摘要

This study introduces a novel approach for non-small cell lung cancer (NSCLC) treatment by developing Bi2Se3-Polysorbate nanoparticles as a multifunctional platform for photothermal therapy and targeted drug delivery. The Bi2Se3-Polysorbates nanoparticles are engineered as innovative photosensitive drug carriers, enhancing biocompatibility through the combination of Bi2Se3 and Polysorbates. Characterization techniques such as Fourier-transform infrared spectroscopy (FT-IR), scanning electron microscopy (SEM), transmission electron microscopy (TEM), and ultraviolet-visible (UV-Vis) spectroscopy confirm the successful synthesis of the nanoparticles. In a breakthrough step, these nanoparticles are combined with a novel heterocyclic drug (drug-1), verified by single-crystal analysis, to create the Bi2Se3-Polysorbates@drug-1 composite. Biological evaluations show that the system significantly inhibits cell proliferation in NSCLC cells, and molecular docking studies reveal that drug-1 interacts with the target protein through hydrogen bonds, halogen bonds, and hydrophobic interactions, suggesting promising anti-cancer activity. This research presents a novel multifunctional nanoplatform for effective drug delivery and offers a new strategy for the treatment of NSCLC, demonstrating significant advancements in cancer therapy.